Group 1 - The stock price of Aladdin (688179) closed at 15.23 yuan on May 23, 2025, down 0.33% with a turnover rate of 1.85% and a trading volume of 51,400 shares, amounting to a transaction value of 78.37 million yuan [1] - On May 23, 2025, the net outflow of main funds was 1.07 million yuan, while the net inflow of speculative funds was 2.67 million yuan, and the net outflow of retail funds was 1.59 million yuan [2][5] Group 2 - Aladdin plans to implement a cash dividend of 1.00 yuan (including tax) for every 10 shares and a capital reserve increase of 2 shares for every 10 shares during the 2024 annual equity distribution [2] - The company announced that part of the bank accounts of its wholly-owned subsidiary, Aladdin Reagents (Shanghai) Co., Ltd., has been frozen, totaling 25,488,459.42 yuan due to a construction contract dispute [3][5] - The frozen amount represents 2.39% of the company's audited net assets for the last year and 5.46% of the audited cash funds, but it is not expected to significantly impact the company's operations [3][5]

Core Viewpoint - The report summarizes the sponsorship and continuous supervision of Shanghai Aladdin Biochemical Technology Co., Ltd. by Western Securities for the issuance of convertible bonds to unspecified objects, highlighting the compliance with regulatory requirements and the company's operational adjustments during the process [1][2]. Group 1: Company Overview - Company Name: Shanghai Aladdin Biochemical Technology Co., Ltd. [2] - Securities Code: 688179.SH [2] - Registered Capital: 277,385,321 Yuan [2] - Registered Address: No. 809, Chuhua Branch Road, Fengxian District, Shanghai [2] - Legal Representative: Xu Jiuzhen [2] - Actual Controllers: Xu Jiuzhen, Zhao Liping [2] - Secretary of the Board: Zhao Xin'an [2] - Type of Securities Issuance: Convertible bonds to unspecified objects [2] - Listing Date: April 12, 2022 [2] - Listing Location: Shanghai Stock Exchange [2] Group 2: Sponsorship Work Overview - The sponsor conducted due diligence and prepared application documents, ensuring compliance with laws and regulations [3][4]. - After obtaining approval from the China Securities Regulatory Commission (CSRC), the sponsor submitted the necessary documents for issuance and listing [3]. Group 3: Continuous Supervision Phase - The sponsor ensured the company adhered to operational norms, commitments, and information disclosure obligations during the continuous supervision phase [4]. - The company adjusted investment amounts and internal investment structures for certain fundraising projects, ensuring no impact on main business operations [5][6]. Group 4: Major Events and Handling - The company approved adjustments to investment amounts for specific projects, reflecting the need for efficient use of raised funds without altering the total investment amount [5]. - The adjustments were approved by the board, supervisory board, shareholders' meeting, and bondholders' meeting, with the sponsor providing verification opinions [5][6]. Group 5: Company Cooperation with Sponsorship - The company provided necessary documents and information for the issuance process, ensuring their authenticity and completeness [6]. - During the continuous supervision phase, the company maintained compliance with regulations and promptly communicated significant events to the sponsor [6][7]. Group 6: Conclusion on Information Disclosure - The sponsor reviewed the company's information disclosure documents, confirming compliance with relevant regulations and ensuring timely and accurate disclosures [7][8]. - The company adhered to the special account storage system for raised funds, with no violations in the use of these funds [8]. Group 7: Remaining Matters - As of December 31, 2024, the company has not fully utilized the raised funds from the convertible bond issuance, and the sponsor will continue to supervise the remaining fund usage and conversion matters [8].